GLP-1s improved outcomes in patients with heart failure with preserved ejection fraction, with or without obesity, but those ...
But if your algorithm serves up wellness and fitness content — like mine does — there’s a good chance you’ve been seeing ...
The pharmaceutical sector's most intense rivalry is escalating. Eli Lilly has unveiled pivotal Phase 3 trial results for its ...
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...
Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.
Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
Pharma marketers enter 2026 asking where DTC fits in the DTP era. | Pharma marketers enter 2026 asking where DTC fits in the ...
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
At the end of the day, GLP-1s can be a powerful tool for achieving your weight loss goals, but only if they're safe and ...
Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...
The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...
In this video, Mikhail Varshavski, DO, who goes by "Dr. Mike," talks with Christle Guevarra, DO, MS, about her struggle with weight, her journey with GLP-1 drugs, and her career in medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback